Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Anetumab Ravtansine in Subjects With Mesothelin-expressing Advanced Solid Cancers and Different Stages of Concurrent Hepatic or Renal Impairment

NCT02696642 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02696642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02696642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Anetumab Ravtansine in Subjects With Mesothelin-expressing Advanced Solid Cancers and Different Stages of Concurrent Hepatic or Renal Impairment
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
April 14, 2016
Completion date
August 19, 2019
Enrollment
54 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms